Abstract
The aim of this study was to examine the reproducibility of the new indicator test for sudomotor function (Neuropad®) in type 2 diabetic patients. The study included 142 type 2 diabetic patients (70 men) with a mean age of 67.3 ± 7.6 years and a mean diabetes duration of 14.2 ± 6.3 years. Sudomotor function was assessed by means of colour change in the indicator test. Each patient was examined twice. Moreover, inter-observer variability was assessed in 60 patients (35 patients with sudomotor dysfunction, 25 patients without sudomotor dysfunction). In the right foot, a highly significant (r = 0.91, p = 0.001) correlation was observed between time until complete colour change of the test on the first (910.7 ± 431.6 seconds) and second examination (935.8 ± 440.1 seconds). In the left foot, a highly significant (r = 0.89, p = 0.001) correlation was observed between time until complete colour change of the test on the first (911.6 ± 430.3 seconds) and second examination (940.5 ± 441.2 seconds). Reproducibility was excellent both in patients with sudomotor dysfunction (p = 0.001) and in those without sudomotor dysfunction (p = 0.001). Agreement in diagnosis of sudomotor dysfunction between the two examinations was 98 %. Inter-observer reproducibility was excellent (p = 0.001), both in patients with sudomotor dysfunction and in those without sudomotor dysfunction. Intra- and interobserver Coefficient of Variance ranged between 4.1 % and 5.1 %. Conclusions: These results indicate that reproducibility of the new indicator test for sudomotor function is excellent in type 2 diabetic patients with or without sudomotor impairment.
Key words
Diabetes mellitus - diabetic peripheral neuropathy - diabetic foot - sudomotor dysfunction
References
-
1
American Diabetes Association and American Academy of Neurology .
Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy.
Diabetes.
1988;
37
1000-1004
-
2
Bax G, Fagherazzi C, Piarulli F, Nicolucci A, Fedele D.
Reproducibility of Michigan Neuropathy Screening Instrument (MNSI).
Diabetes Care.
1996;
19
904-905
-
3
Boulton A JM, Gries F A, Jervell J.
Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy.
Diabet Med.
1998;
15
508-514
-
4
Boulton A JM, Kirsner R S, Vileikyte L.
Neuropathic diabetic foot ulcers.
N Engl J Med.
2004 a;
351
48-55
-
5
Boulton J AM.
The diabetic foot: from art to science. The 18th Camillo Golgi lecture.
Diabetologia.
2004 b;
47
1343-1353
-
6 Budavari S, O'Neil M J, Smith A, Heckelman P E, Kinneary (eds) J F. The Merck Index. An Encyclopaedia of Chemicals, Drugs and Biologicals. 12th edn. New Jersey; Merck Research Laboratories 1996: 2503
-
7
Duby J J, Campbell R K, Setter S M, White J R, Rasmussen K A.
Diabetic neuropathy: an intensive review.
Am J Health Syst Pharm.
2004;
61
160-173
-
8
Edmonds M E.
The diabetic foot, 2003.
Diabetes Metal Res Rev.
2004;
20 (Suppl 1)
S9-S12
-
9
Kempler P.
Autonomic neuropathy: a marker of cardiovascular risk.
Br J Diabetes Vasc Dis.
2003;
3
84-90
-
10
La Cava E C.
Your nerves. Neuropathy affects more than 50 percent of people with diabetes. Here's what you can do to prevent it.
Diabetes Forecast.
2002;
55
67-69
-
11 Low P A. Sudomotor function. Gries FA, Low PA, Cameron NE, Ziegler D Textbook of Diabetic Neuropathy. Stuttgart; Georg Thieme Verlag 2003: 274-278
-
12
Papanas N, Papatheodorou K, Christakidis D, Papazoglou D, Giassakis G, Piperidou H, Monastiriotis C, Maltezos E.
Evaluation of a new indicator test for sudomotor function (Neuropad®) in the diagnosis of peripheral neuropathy in type 2 diabetic patients.
Exp Clin Endocrinol Diabetes.
2005;
113
1-4
-
13
Perkins B A, Bril V.
Diabetic neuropathy: a review emphasizing diagnostic methods.
Clin Neurophysiol.
2003;
114
1167-1175
-
14
Petit Jr W A, Upender R P.
Medical evaluation and treatment of diabetic peripheral neuropathy.
Clin Pediatr Med Surg.
2003;
20
671-688
-
15
Reiber G E, Vileikyte L, Boyko E J, del Aguila M, Smith D G, Lavery L A, Boulton A JM.
Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings.
Diabetes Care.
1999;
22
157-162
-
16
Valensi P, Attali J R, Gagant S.
Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
Diabet Med.
1993;
10
933-939
-
17
Vinik A I, Maser R E, Mitchell B D, Freeman R.
Diabetic autonomic neuropathy: Technical review.
Diabetes Care.
2003;
26
1553-1579
-
18
Young J A.
Cobalt (II) chloride hexahydrate.
J Chem Edu.
2003;
80
610
-
19
Zick R, Schäper T, Deeters U.
Periphere diabetische Neuropathie. Die Schweißsekretion am Fuß messen.
Klinikarzt.
2003;
32
192-194
Dr. Nikolaos Papanas
Ethnikis Antistasis 44
Alexandroupolis 68100
Greece
Phone: + 302551084972
Fax: + 30 25 51 07 47 23
Email: papanasnikos@yahoo.gr